Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 0.76 |
| ▸ | MMP9 | P14780 | 19/20 | 0.76 |
| ▸ | MMP14 | P50281 | 16/20 | 0.76 |
| ▸ | MMP8 | P22894 | 9/20 | 0.76 |
| ▸ | MMP3 | P08254 | 7/20 | 0.76 |
| ▸ | MMP7 | P09237 | 4/20 | 0.76 |
| ▸ | MMP1 | P03956 | 1/20 | 0.76 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684163 | 0.87 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL2381073 | 0.84 | MMP2 (0.78) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL10187458 | 0.81 | MMP2 (0.76) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL10239044 | 0.81 | MMP2 (0.73) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL10238440 | 0.80 | MMP2 (0.80) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL10238442 | 0.78 | MMP2 (0.53) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL10238412 | 0.77 | MMP2 (0.56) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL18184671 | 0.77 | PSIP1 (0.59) | — | |
| SCHEMBL10238448 | 0.76 | MMP2 (0.78) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL315578 | 0.75 | MMP2 (0.65) | MMP2MMP9MMP14MMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681209-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2681209-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2681209-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | Aquilus Pharmaceuticals, Inc (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130338116-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | SUCHOLEIKI IRVING (US) | 2013-12-19 | — | — | US | disclosed |
| US-8530453-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530453-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530453-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2012118498-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS, INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012118498-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS, INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | MMP2 3/4885MMP9 1/4885MMP14 15/4885 |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | MMP9, MMP1, MMP2 | MMP2 3/4885MMP9 1/4885MMP14 16/4885 |
| US-20130338116-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | MMP9, MMP10, MMP3 | MMP2 5/4885MMP9 1/4885MMP14 6/4885 |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | MMP9, MMP10, MMP3 | MMP2 5/4885MMP9 1/4885MMP14 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.